PROS1 and cancer: Obvious potential applications are TME-dependent cytosolic delivery of nanobodies, single chain variable fragments, affibodies, DARPins, and other protein-based entities that bind to intracellular pathologically altered proteins (e.g., against BCR-ABL oncogenic protein [82], RAS [83], or LMO2 [84]) in cancer cells.